Travere Therapeutics (TVTX) Depreciation & Amortization (CF) (2013 - 2026)

Travere Therapeutics has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $25.2 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 96.94% year-over-year to $25.2 million; the trailing twelve-month figure through Mar 2026 stood at $73.2 million (up 57.4% YoY), and the FY2025 full-year result was $60.7 million, up 39.46% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $25.2 million, up from $18.1 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $25.2 million in Q1 2026, with the low at -$793000.0 in Q3 2022.
• Historically, Depreciation & Amortization (CF) has averaged $11.1 million across 5 years, with a median of $10.9 million in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) tumbled 110.07% — and 2023, when it soared 1547.04%.
• Travere Therapeutics' Depreciation & Amortization (CF) stood at $6.3 million in 2022, then surged by 50.32% to $9.5 million in 2023, then gained by 27.43% to $12.1 million in 2024, then surged by 50.0% to $18.1 million in 2025, then soared by 39.01% to $25.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $25.2 million (Q1 2026), $18.1 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.